These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 25289657

  • 1. Associations of inflammatory cytokines with choroidal neovascularization in highly myopic eyes.
    Yamamoto Y, Miyazaki D, Sasaki S, Miyake K, Kaneda S, Ikeda Y, Baba T, Yamasaki A, Noguchi Y, Inoue Y.
    Retina; 2015 Feb; 35(2):344-50. PubMed ID: 25289657
    [Abstract] [Full Text] [Related]

  • 2. Effect of intravitreal ranibizumab injections on aqueous humour concentrations of vascular endothelial growth factor and pigment epithelium-derived factor in patients with myopic choroidal neovascularisation.
    Costagliola C, Semeraro F, dell'Omo R, Romano MR, Russo A, Aceto F, Mastropasqua R, Porcellini A.
    Br J Ophthalmol; 2015 Jul; 99(7):1004-8. PubMed ID: 25770144
    [Abstract] [Full Text] [Related]

  • 3. Vascular endothelial growth factor in the aqueous humour in eyes with myopic choroidal neovascularization.
    Sawada O, Kawamura H, Kakinoki M, Sawada T, Ohji M.
    Acta Ophthalmol; 2011 Aug; 89(5):459-62. PubMed ID: 20102348
    [Abstract] [Full Text] [Related]

  • 4. The landscape of angiogenesis and inflammatory factors in eyes with myopic choroidal neovascularization before and after anti-VEGF injection.
    Wang T, Lian P, Zhan J, Li Y, Liu B, Zhao X, Wu Q, Li H, Lu L, Chen S.
    Cytokine; 2024 Jul; 179():156640. PubMed ID: 38735245
    [Abstract] [Full Text] [Related]

  • 5. Intraocular Cytokines and Their Correlations with Clinical Parameters in Patients with Myopic Choroidal Neovascularization.
    Shchuko AG, Zaitseva NV, Yurieva TN, Chernykh ER, Mikhalevich IM, Shevela EY, Grigorieva AV.
    Ophthalmologica; 2017 Jul; 237(2):96-104. PubMed ID: 28103602
    [Abstract] [Full Text] [Related]

  • 6. Aqueous humor cytokine levels in patients with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration.
    Sakurada Y, Nakamura Y, Yoneyama S, Mabuchi F, Gotoh T, Tateno Y, Sugiyama A, Kubota T, Iijima H.
    Ophthalmic Res; 2015 Jul; 53(1):2-7. PubMed ID: 25472810
    [Abstract] [Full Text] [Related]

  • 7. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
    Yang HS, Kim JG, Kim JT, Joe SG.
    Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
    [Abstract] [Full Text] [Related]

  • 8. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia.
    Chan WM, Lai TY, Chan KP, Li H, Liu DT, Lam DS, Pang CP.
    Retina; 2008 Oct; 28(9):1308-13. PubMed ID: 18728623
    [Abstract] [Full Text] [Related]

  • 9. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results.
    Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F, Tano Y.
    Am J Ophthalmol; 2009 Jan; 147(1):94-100.e1. PubMed ID: 18774550
    [Abstract] [Full Text] [Related]

  • 10. Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization.
    Yodoi Y, Tsujikawa A, Nakanishi H, Otani A, Tamura H, Ojima Y, Hayashi H, Yoshimura N.
    Am J Ophthalmol; 2009 May; 147(5):816-24, 824.e1. PubMed ID: 19211092
    [Abstract] [Full Text] [Related]

  • 11. Profile of intraocular immune mediators in patients with age-related macular degeneration and the effect of intravitreal bevacizumab injection.
    Agawa T, Usui Y, Wakabayashi Y, Okunuki Y, Juan M, Umazume K, Kezuka T, Takeuchi M, Yamauchi Y, Goto H.
    Retina; 2014 Sep; 34(9):1811-8. PubMed ID: 24801651
    [Abstract] [Full Text] [Related]

  • 12. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization.
    Ruiz-Moreno JM, Montero JA, Arias L, Araiz J, Gomez-Ulla F, Silva R, Piñero DP.
    Retina; 2010 Sep; 30(10):1609-15. PubMed ID: 20856171
    [Abstract] [Full Text] [Related]

  • 13. Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with amd after bevacizumab treatment.
    Roh MI, Kim HS, Song JH, Lim JB, Koh HJ, Kwon OW.
    Retina; 2009 Apr; 29(4):523-9. PubMed ID: 19262441
    [Abstract] [Full Text] [Related]

  • 14. Association between choroidal morphology and anti-vascular endothelial growth factor treatment outcome in myopic choroidal neovascularization.
    Ahn SJ, Woo SJ, Kim KE, Park KH.
    Invest Ophthalmol Vis Sci; 2013 Mar 01; 54(3):2115-22. PubMed ID: 23462751
    [Abstract] [Full Text] [Related]

  • 15. Intravitreal bevacizumab in myopic neovascular membranes: 24-month results.
    Ruiz-Moreno JM, López-Gálvez MI, Montero Moreno JA, Pastor Jimeno JC.
    Ophthalmology; 2013 Jul 01; 120(7):1510-1.e1. PubMed ID: 23823510
    [No Abstract] [Full Text] [Related]

  • 16. Long-term outcomes of anti-vascular endothelial growth factor therapy with and without posterior scleral reinforcement on myopic maculopathy in myopic choroidal neovascularization eyes.
    Kang MT, Wang N, Xu W, Yusufu M, Liu W, Tian J, Qi Y.
    BMC Ophthalmol; 2024 Mar 13; 24(1):118. PubMed ID: 38481176
    [Abstract] [Full Text] [Related]

  • 17. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia.
    Sakaguchi H, Ikuno Y, Gomi F, Kamei M, Sawa M, Tsujikawa M, Oshima Y, Kusaka S, Tano Y.
    Br J Ophthalmol; 2007 Feb 13; 91(2):161-5. PubMed ID: 16914470
    [Abstract] [Full Text] [Related]

  • 18. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization.
    Yoon JU, Kim YM, Lee SJ, Byun YJ, Koh HJ.
    Retina; 2012 May 13; 32(5):949-55. PubMed ID: 22534553
    [Abstract] [Full Text] [Related]

  • 19. Aqueous humor levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization. A prospective, case-control study.
    dell'Omo R, Cassetta M, dell'Omo E, di Salvatore A, Hughes JM, Aceto F, Porcellini A, Costagliola C.
    Am J Ophthalmol; 2012 Jan 13; 153(1):155-61.e2. PubMed ID: 21861975
    [Abstract] [Full Text] [Related]

  • 20. Three versus one intravitreal bevacizumab injections as initial protocol to treat myopic choroidal neovascularization.
    Ruiz-Moreno JM, Montero JA, Arias L, Araiz J, Gomez-Ulla F, Silva R, Piñero DP.
    Acta Ophthalmol; 2012 Feb 13; 90(1):e82-3. PubMed ID: 21470378
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.